Publications by authors named "Xavier Armario"
Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study.
JACC Cardiovasc Interv
February 2024
Article Synopsis
- The COVID-19 pandemic led to significant treatment delays for patients needing transcatheter aortic valve replacement (TAVR), with a marked decrease in procedure volumes during the first two waves of the pandemic.
- The study analyzed TAVR case data from 130 centers in 61 countries, finding a 15% drop in cases during the first wave and 7% in the second, particularly affecting regions like Africa, Central-South America, and Asia.
- Factors such as hospital type (private vs public), urban vs rural location, low procedure volumes, a country's socioeconomic status, and stringent public health measures contributed to these reductions, highlighting the need for improved public health policies for future health crises.
Center Valve Preference and Outcomes of Transcatheter Aortic Valve Replacement: Insights From the AMTRAC Registry.
JACC Cardiovasc Interv
June 2022
Background: Data on outcomes of transcatheter aortic valve replacement (TAVR) using balloon-expandable valves (BEVs) or self-expandable valves (SEVs) as well as the impact of center valve preference on these outcomes are limited.
Objectives: The aim of this study was to compare outcomes of TAVR procedures using third-generation BEVs and SEVs stratified by center valve preference.
Methods: In a multicenter registry (n = 17), 13 centers exhibited valve preference (66.
Article Synopsis
- This study aimed to assess the outcomes of patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) using the 34 mm Evolut R valve.
- It was found that while this valve had a device success rate of 87.4%, it also led to a higher rate of permanent pacemaker implantation (22.4%) compared to other valve sizes.
- Overall, the 34 mm Evolut R performed similarly to other valve sizes in terms of device success, indicating its effectiveness despite the increased pacemaker requirement.
Background: The ACURATE neo™ is a novel, second-generation self-expanding supra-annular transcatheter heart valve (THV). The objective of this multi-centre registry is to assess the safety, clinical utility, and impact of 'learning-curve-experience' (LCE) on transcatheter aortic valve replacement outcomes in the United Kingdom (UK) and Ireland.
Methods: We prospectively collected data from seven ACURATE neo™ THV implanting centres (n = 484) between February 2016 and November 2020.
Background: The mean age of transcatheter aortic valve implantation (TAVI) patients is steadily decreasing.
Aims: The aim of the study was to describe the characteristics, the indications for and the outcomes of TAVI in patients <70 years old.
Methods: All patients undergoing TAVI (n=8,626) from the 18 participating centres between January 2007 and June 2020 were stratified by age (70).
Horizontal Aorta in Transcatheter Self-Expanding Valves: Insights From the HORSE International Multicentre Registry.
Circ Cardiovasc Interv
September 2021
[Figure: see text].
View Article and Find Full Text PDFBackground: Horizontal aorta (HA) is an anatomical feature that can pose significant technical challenges for the successful positioning of the bioprosthetic valve during transcatheter aortic valve replacement (TAVR). Physiological range of aortic angle (AA) is unknown; hence there is no cutoff AA for classifying HA. Moreover, patient characteristics predicting HA are under-investigated.
View Article and Find Full Text PDFEffect of Transcatheter Aortic Valve Replacement on Concomitant Mitral Regurgitation and Its Impact on Mortality.
JACC Cardiovasc Interv
June 2021
Objectives: The purpose of this study was to examine the impact of residual mitral regurgitation (MR) on mortality in patients undergoing transcatheter aortic valve replacement (TAVR).
Background: MR is common in patients undergoing TAVR. Data on optimal management of patients with significant MR after TAVR are limited.
Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience.
JACC Cardiovasc Interv
January 2021
Objectives: The aim of this study was to evaluate the short-term safety and efficacy of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge system.
Background: The LOTUS Edge system was commercially re-released in April 2019. The authors report the first European experience with this device.
Background The clinical significance of conduction disturbances after transcatheter aortic valve implantation has been described; however, little is known about the influence of baseline ECGs in the prognosis of these patients. Our aim was to study the influence of baseline ECG parameters, including interatrial block (IAB), in the prognosis of patients treated with transcatheter aortic valve implantation. Methods and Results The BIT (Baseline Interatrial Block and Transcatheter Aortic Valve Implantation) registry included 2527 patients with aortic stenosis treated with transcatheter aortic valve implantation.
View Article and Find Full Text PDF